HEALTH
The portal will strengthen interdepartmental synergies and increase efficacy in functioning of GoI Departments/ Agencies involved in the consideration of cases related to transfer of human biological material. This will streamline the regulatory process and ensure transparent and regulated export of human biological material in compliance with national regulations
By TEAM CIRCULAR EXPRESS • 16 Aug 2026
👁 2 views
The Directorate General of Foreign Trade has issued a notification amending the import and export policy for human biological samples used for commercial purposes. Indian diagnostic laboratories and clinical research centers are now permitted to import or export these samples for lab analysis or R&D testing without prior government agency approvals. This is subject to the submission of an undertaking to Customs authorities at the port of entry or exit. The undertaking must confirm adherence to all applicable safety, transfer, and disposal regulations set by WHO, DGFT, and the Ministry of Environment, Forests and Climate Change. This policy change aims to streamline the movement of biological samples for research and diagnostic activities.
City
New Delhi
State
Delhi
purpose of issuance
To amend the import/export policy for human biological samples for commercial purposes by removing the requirement for prior government agency approvals, provided an undertaking is submitted to Customs.
Most Important Details
Indian diagnostic labs and clinical research centers can import/export human biological samples for R&D/lab analysis without prior permits, provided they submit an undertaking to Customs authorities regarding compliance with WHO, DGFT, and Ministry of Environment safety and disposal regulations.
City_2
New Delhi
State_2
Delhi
purpose of issuance_2
To amend the import/export policy for human biological samples for commercial purposes by removing the requirement for prior government agency approvals, provided an undertaking is submitted to Customs.
Most Important Details_2
Indian diagnostic labs and clinical research centers can import/export human biological samples for R&D/lab analysis without prior permits, provided they submit an undertaking to Customs authorities regarding compliance with WHO, DGFT, and Ministry of Environment safety and disposal regulations.
🔒 Document — view only
Regards, Circular Express
Similar Circulars
Policy Brief on Active Case Finding and TB Control Strategy among Saharia Tribes in Madhya Pradesh
#Health#ICMR#Jabalpur
ICMR-DHR Policy on Biomedical Innovation and Entrepreneurship
#Education#Health#ICMR
ICMR Research Brief on COVID-19 Stigma Correlates and Mitigation Strategies
#Delhi#Health#ICMR
Population Estimation and Statistical Methods for Cancer Incidence Analysis in Bhopal
#Bhopal#Health#ICMR
Family Dots to Prevent Treatment Loss to Follow up in Hard to reach Areas of Kondagaon District,Chhattisgarh state,India
#Chhattisgarh#Health#ICMR
Overview of Population Based Cancer Registry in Tripura
#Health#ICMR#Tripura
You are viewing
The portal will strengthen interdepartmental synergies and increase efficacy in functioning of GoI Departments/ Agencies involved in the consideration of cases related to transfer of human biological material. This will streamline the regulatory process and ensure transparent and regulated export of human biological material in compliance with national regulations
For Circular Express Members Only
Enter your registered 10-digit mobile number to view this circular.
Member Verified
LOGIN FOR PERMANENT ACCESSOne Time Access shows this circular only. Login keeps you signed in for all circulars.
HEALTH
The portal will strengthen interdepartmental synergies and increase efficacy in functioning of GoI Departments/ Agencies involved in the consideration of cases related to transfer of human biological material. This will streamline the regulatory process and ensure transparent and regulated export of human biological material in compliance with national regulations
By TEAM CIRCULAR EXPRESS • 16 Aug 2026
👁 2 views
The Directorate General of Foreign Trade has issued a notification amending the import and export policy for human biological samples used for commercial purposes. Indian diagnostic laboratories and clinical research centers are now permitted to import or export these samples for lab analysis or R&D testing without prior government agency approvals. This is subject to the submission of an undertaking to Customs authorities at the port of entry or exit. The undertaking must confirm adherence to all applicable safety, transfer, and disposal regulations set by WHO, DGFT, and the Ministry of Environment, Forests and Climate Change. This policy change aims to streamline the movement of biological samples for research and diagnostic activities.
City
New Delhi
State
Delhi
purpose of issuance
To amend the import/export policy for human biological samples for commercial purposes by removing the requirement for prior government agency approvals, provided an undertaking is submitted to Customs.
Most Important Details
Indian diagnostic labs and clinical research centers can import/export human biological samples for R&D/lab analysis without prior permits, provided they submit an undertaking to Customs authorities regarding compliance with WHO, DGFT, and Ministry of Environment safety and disposal regulations.
City_2
New Delhi
State_2
Delhi
purpose of issuance_2
To amend the import/export policy for human biological samples for commercial purposes by removing the requirement for prior government agency approvals, provided an undertaking is submitted to Customs.
Most Important Details_2
Indian diagnostic labs and clinical research centers can import/export human biological samples for R&D/lab analysis without prior permits, provided they submit an undertaking to Customs authorities regarding compliance with WHO, DGFT, and Ministry of Environment safety and disposal regulations.
🔒 Document — view only
Regards, Circular Express
Similar Circulars
Policy Brief on Active Case Finding and TB Control Strategy among Saharia Tribes in Madhya Pradesh
#Health#ICMR#Jabalpur
ICMR-DHR Policy on Biomedical Innovation and Entrepreneurship
#Education#Health#ICMR
ICMR Research Brief on COVID-19 Stigma Correlates and Mitigation Strategies
#Delhi#Health#ICMR
Population Estimation and Statistical Methods for Cancer Incidence Analysis in Bhopal
#Bhopal#Health#ICMR
Family Dots to Prevent Treatment Loss to Follow up in Hard to reach Areas of Kondagaon District,Chhattisgarh state,India
#Chhattisgarh#Health#ICMR
Overview of Population Based Cancer Registry in Tripura
#Health#ICMR#Tripura
